The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
India's drug regulator is cracking down on GLP-1 weight loss drugs due to improper sales and promotions. Inspections across 49 entities revealed violations, leading to notices and potential license cancellations. With semaglutide generics now available post-patent expiry, authorities emphasize prescription-only use by specialists.
The Telangana Drugs Control Administration (DCA) has issued a strong warning against unsupervised use of semaglutide, a popular GLP-1 drug for weight loss and Type-2 diabetes management. With generics now available from Sun Pharma, Dr. Reddy's, Zydus, and Glenmark following patent expiry, demand is surging—but so are risks like acute pancreatitis and kidney injury. Always consult a doctor for proper assessment and prescription.
Demand for GLP-1 drugs like Wegovy and Zepbound is booming, with 1 in 8 Americans now using them. But experts warn: medication alone isn't enough—pairing with healthy habits like protein-rich meals, exercise, and sleep amplifies weight loss and health gains, per recent studies.
Alkem Laboratories is revolutionizing GLP-1 access in India with its new semaglutide injection, priced at just Rs450 per week. Branded as Semasize, Obesema, and Hepaglide, this once-weekly therapy targets Type 2 diabetes and chronic weight management. Learn about its approvals, innovative pens, and potential impact on affordable care.
Scientists have uncovered a satiety-signaling molecule in python blood that surges dramatically after meals, potentially paving the way for healthier weight loss without the nausea common in drugs like Ozempic. This discovery from pythons' feast-and-fast metabolism highlights a new biological pathway involving gut bacteria. Could pTOS be the key to natural appetite control?
Hims & Hers has resolved its dispute with Novo Nordisk, shifting to official weight loss drugs like Wegovy over controversial compounded GLP-1 alternatives. This brings legal clarity but slams profitability with higher costs and a cautious Q1 2026 revenue outlook of $600-625 million. With 2.5 million subscribers, can the stock rebound amid debt and investigations?
Semaglutide prices in India have plummeted by up to 90% following the launch of over 15 generic versions just days after patent expiry. Major players like Sun Pharma, Zydus Lifesciences, Dr Reddy's, and Natco are offering affordable options for type 2 diabetes and obesity management. This shift promises greater access to this vital GLP-1 agonist therapy.
Recent trials show about 10% of people using Wegovy and Ozempic experience minimal weight loss, classified as 'non-responders.' Despite average reductions of 15-20%, stories like Samantha Jess's highlight real challenges. Discover why GLP-1 drugs don't work for everyone and how to optimize results.
Trials show one in ten people on Wegovy and Ozempic lose less than 5% of their body weight, challenging the drugs' reputation as a universal solution. Patient experiences like Samantha Jess's highlight non-responder realities, while experts explain genetic and metabolic factors. Discover why GLP-1 agonists work for some but not others.
